Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson выглядит качественным, но не дешёвым защитным активом: сильная рентабельность сочетается с заметной премией по мультипликаторам. P/E, P/S, P/B и P/FCF все выше медианы отрасли, причём особенно выделяются P/B и P/S, что ограничивает потенциал дальнейшего переоценивания. При этом динамика прибыли и эффективности в целом положительная: ROE, ROA и ROI находятся на высоких уровнях и растут по годам, а чистая и операционная маржа остаются существенно выше отраслевых ориентиров. Выручка держится стабильно около 24 млрд долларов в квартальном/TTM выражении, а валовая прибыль и чистая прибыль подтверждают способность компании генерировать устойчивый денежный поток. С другой стороны, краткосрочная ликвидность слабее комфортной: quick ratio ниже 1, current ratio лишь около 1, что для инвестора означает ограниченный запас прочности по оборотному капиталу. Долговая нагрузка не выглядит критичной, но долг к капиталу и долгосрочный долг остаются заметными и немного растут, поэтому баланс нельзя назвать безрисковым. Дивидендная доходность снизилась относительно прошлых периодов, а значит дивидендный аргумент сейчас поддерживает оценку меньше, чем раньше. EBITDA в последнем TTM ниже некоторых прошлых квартальных значений, что добавляет осторожности к краткосрочному темпу операционного роста. В то же время рост собственного капитала и активов говорит о сохранении масштабной и устойчивой базы бизнеса. В сумме фундаментал скорее оправдывает премию к рынку, но не настолько высокую, чтобы агрессивно поднимать целевую цену. Для инвестора это история про качество, стабильность и защитный профиль, но с ограниченным апсайдом из-за уже дорогой оценки.

Johnson & Johnson

Сильный индекс, без изменений. Быки в растерянности.

Strong index, flat. The bulls are confused.

Сильный индекс, без изменений. Рынок на стороне быков.

Strong index, flat. The market is on the bulls' side.

Средний индекс, значительно вырос. Увеличился приток средств в лонги.

Medium index, significantly up. The inflow of funds into longs has increased.

JNJ остаётся качественной защитной историей с сильной рентабельностью и стабильной прибылью, но высокая оценка и слабая ликвидность ограничивают апсайд.

Johnson & Johnson (JNJ) closed the most recent trading day at $240.87, moving +1.07% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.5%. At the same time, the Dow added 0.7%, and the tech-heavy Nasdaq gained 0.31%.
The world's biggest maker of health care products's shares have seen an increase of 3.26% over the last month, not keeping up with the Medical sector's gain of 5.49% and outstripping the S&P 500's loss of 0.23%.
The investment community will be paying close attention to the earnings performance of Johnson & Johnson in its upcoming release. The company is slated to reveal its earnings on July 15, 2026. The company's earnings per share (EPS) are projected to be $2.83, reflecting a 2.17% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $25.04 billion, indicating a 5.46% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $11.57 per share and revenue of $100.81 billion. These totals would mark changes of +7.23% and +7.02%, respectively, from last year.
Investors should also take note of any recent adjustments to analyst estimates for Johnson & Johnson. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.04% lower within the past month. At present, Johnson & Johnson boasts a Zacks Rank of #3 (Hold).
Looking at valuation, Johnson & Johnson is presently trading at a Forward P/E ratio of 20.6. This represents a premium compared to its industry average Forward P/E of 15.58.
It's also important to note that JNJ currently trades at a PEG ratio of 2.33. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.71 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 113, this industry ranks in the top 47% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts

Key Points
Cancer remains the pharmaceutical industry's biggest business, as well as one of its fastest-growing.
Some technological leaps complement existing cancer drug know-how.
Johnson & Johnson intends to combine its own recent acquisitions and developmental work with a separate but complementary biopharma development.
The pharmaceutical industry continues to address any and every known ailment. Cancer, however, remains the business's biggest market. Precedence Research suggests the global oncology market is currently worth nearly $280 billion per year, en route to $700 billion by 2035.
And that bodes well for drugmaker Johnson & Johnson (NYSE: JNJ). After years of lethargic performance, the company's been on a buying spree of late, acquiring Halda Therapeutics and Ambrx Biopharma specifically because of the developmental work these companies were doing on the cancer front.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Fast-forward to today. J&J's most recent purchase -- while relatively small at $1 billion -- advances the company's goal of producing $50 billion worth of annual oncology revenue by 2030. (For perspective, Johnson & Johnson did $94.2 billion worth of business last year.)
Here's what investors need to know about the deal.
A strategic, complementary acquisition
The latest target in Johnson & Johnson's streak of acquisitions is mostly unknown Firefly Bio. What's it getting for its $1 billion in cash? Firefly's proprietary Firelink degrader antibody conjugate (DAC) platform, mostly, which specifically takes aim at KRAS (Kirsten rat sarcoma viral oncogene homolog) tumors.
That won't mean much to most people; here's the explanation in simpler language:
A KRAS-driven tumor is a cancer caused by a mutation in the KRAS gene. This mutation errantly tells the affected cell to continue growing and dividing even when it shouldn't. It's not uncommon in cases of colorectal and non-small cell lung cancer, and it's particularly common with pancreatic cancer. It's a problem in all cases, however, in that it's long been considered "undruggable," meaning there's historically been little that can be done about these mutations.
Medical science's capabilities have finally caught up with many of its diagnostic capabilities, though, at least on one front. The industry can now induce a human body to natural fight cancers it didn't know -- or know how -- to fight before. One of the approaches of inducing such a response is with antibody drug conjugates, which essentially deliver self-destruct instructions to diseased cells (identifying them by unique proteins on their surface) without harming healthy cells.
Enter FireFly Bio, or specifically, the Firelink platform, which creates a category of antibody drug conjugates (or ADCs) called "degraders." These are essentially ADC boosters that destroy a unique gatekeeping protein on the surface of a diseased cell without ever even giving it a chance to prevent or slow an antibody from effectively penetrating it.
A chance for marketable improvement
It's still a fairly new science, but one that's more than proven. The next stage of the DAC era is simply continuing to refine the science so it can be utilized with more cancer-fighting antibody drug conjugates. And Johnson & Johnson's got plenty of those. That's the chief reason it wanted Ambrx back in 2024, although it's done a fair amount of internal ADC development lately as well.
It matters mostly because Precedence Research also thinks the worldwide antibody drug conjugate market alone could be worth $21 billion by 2030, and $35 billion by 2035. The more effective J&J's cancer-fighting ADC portfolio is, the bigger its piece of that pie gets, and the closer it gets to its cancer treatment revenue target of $50 billion.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $438,283!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,257,427!*
Now, it’s worth noting Stock Advisor’s total average return is 938% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of Cancer's Most "Undruggable" Targets. Why That's Very Good News for Investors.

(RTTNews) - This week, the biotech sector saw a surge of FDA, EU, and China approvals spanning oncology, dermatology, autoimmune and rare disease indications. Strategic acquisitions and licensing deals drove pipeline expansion, while positive clinical readouts in obesity, MASLD, and autoimmune disorders reinforced investor confidence in innovation and therapeutic breadth.
Let's dive into the details.
FDA Approvals
Guardant Health, Inc. (GH) secured FDA approval for its Guardant360 CDx, a liquid biopsy test, as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertinib tablets), the first targeted therapy for adults with HER2-mutant advanced non-small cell lung cancer (NSCLC).
The blood-based test enables rapid genomic profiling to guide treatment decisions, underscoring the growing role of liquid biopsy in advanced cancer care.
GH closed Thursday's trading (June 11, 2026) at $130.90, up 0.15%
Eli Lilly and Company (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS or lebrikizumab-lbkz (250 mg/2 mL) in moderate-to-severe atopic dermatitis, expanding beyond its once-monthly schedule. Backed by Phase 3 Adjoin extension data, the regimen showed durable disease control with no new safety signals, offering patients fewer injections—just six times a year.
EBGLYSS sales surged 141% in Q1 2026 to $145 million from $60 million in the prior year, reflecting strong uptake in Lilly's growing immunology portfolio.
LLY closed Thursday's trading at $1,160.95, up 2.16%
Vor Bio (VOR) announced that Telitacicept (developed by RemeGen) has received approval from China's NMPA for the treatment of adult patients with Sjögren's disease.
This marks the first and only approved therapy for the chronic autoimmune condition in China, supported by positive Phase 3 trial data showing improvements in systemic disease activity and patient-reported outcomes.
VOR closed Thursday's trading at $14.09, up 8.38%
Sanofi (SNY) announced European Commission approved Sarclisa Sc (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patietns eligible for transplant. The clearance expands Sarclisa's use beyond relapsed settings, supported by Phase 3 IRAKLIA trial results which showed significant progression-free survival benefit. The decision expands Sarclisa's use into the frontline transplant-eligible setting, reinforcing its role in advancing treatment options for multiple myeloma.
SNY closed Thursday's trading at $44.11, up 1.24%
Pfizer Inc. (PFE) announced that the FDA has approved HYMPAVZI for additional patient groups, including individuals aged 12 and older with hemophilia A or B who develop inhibitors, and children aged 6-11 with or without inhibitors.
Supported by Phase 3 BASIS trial data, the therapy demonstrated a 93% reduction in annualized bleeding rates and consistent safety. This marks the first subcutaneous non-factor therapy available for pediatric hemophilia B, reinforcing Pfizer's commitment to advancing rare disease care.
PFE closed Thursday's trading at $26.17, up 2.23%
Amneal Pharmaceuticals, Inc. (AMRX) announced FDA approval of Romidepsin injection solution as a single-dose supply in a ready-to-use vial for the treatment of cutaneous T-cell lymphoma.
The product was previously manufactured by Teva under the brand name ISTODAX, but later withdrawn from the U.S. market. Amneal's relaunch brings the therapy back to market in a streamlined format.
AMRX closed Thursday's trading at $16.34, up 6.66%
Deals
Teva Pharmaceutical Industries Limited?(TEVA) completed the acquisition of Emalex Biosciences for $700 million in consideration, with the potential for up to an additional $200 million in commercial milestone payments, as well as other contingent payments.
The acquisition adds Ecopipam, an investigational asset in a Phase 3 trial for pediatric Tourette syndrome, to Teva's pipeline. NDA submission is expected in H2 2026.
TEVA closed Thursday's trade at $34.56, up 2.92%.
GSK plc (GSK) entered into an agreement to acquire Nuvalent, Inc (NUVL), which develops targeted cancer therapies, in a transaction valued at $10.6 billion (£8.0 billion) to bolster its oncology pipeline.
Under the terms, GSK will commence a tender offer to acquire all outstanding Nuvalent shares at $124 each in cash, and the transaction is expected to close in the third quarter of 2026, subject to regulatory conditions.
GSK closed Thursday's trade at $53.15, up 0.55%.
NUVL closed Thursday's trade at $123.45, up 0.08%.
Johnson & Johnson To Acquire Firefly Bio For $1 Bln Cash Deal for Oncology Pipeline Expansion
Johnson & Johnson (JNJ)?entered into a definitive agreement to acquire Firefly Bio, Inc., including its proprietary Firelink degrader antibody conjugate (DAC) platform for KRAS-driven tumours, for $1 billion in cash and the transaction is expected to occur later this year, subject to approvals. The deal is expected to help JNJ expand its oncology portfolio.
JNJ closed Thursday's trade at $238.33, down 0.07%.
Cartesian Therapeutics Inc. (RNAC) has inked a strategic licensing agreement with WestGene Biopharma Co., Ltd. to advance the development of novel in vivo chimeric antigen receptor T-cell (CAR-T) therapies in autoimmune diseases.
Cartesian's lead asset is Descartes-08, an autologous mRNA CAR-T targeting B-cell maturation antigen (BCMA).
In partnership with WestGene, Cartesian will conduct a Phase 1 dose-escalation study of the mRNA used in Descartes-08 delivered via WestGene's proprietary targeted lipid nanoparticles (tLNPs) in patients with generalized myasthenia gravis. This study is expected to be initiated in 2H 2026, with topline data anticipated in 1H 2027.
RNAC closed Thursday's trade at $8.06, up 8.48%
Galmed Pharmaceuticals Ltd. (GLMD) announced a definitive agreement to acquire Colospan Ltd., a commercial-stage medical device company focused on colorectal surgery. The acquisition includes Colospan's flagship product, CG-100, an intraluminal bypass device placed inside the bowel after colorectal surgery that allows waste to pass through it while protecting the stitched connection for healing.
CG-100 has the FDA BDD designation and is CE-marked, and Colospan is also conducting a pivotal U.S. clinical trial. Galmed plans to invest $6 million to launch the device in Europe during the second half of 2026, initially targeting Germany, Austria, and Switzerland.
GLMD closed Thursday's trade at $0.61, up 17.31%
LENZ Therapeutics, Inc. (LENZ)?announced that Everest Medicines (1952.HK) has acquired rights to develop, manufacture and commercialise VIZZ (aceclidine ophthalmic solution 1.44%)?in Greater China, including mainland China, Hong Kong (SAR), Macao (SAR) and Taiwan.
In return for the rights granted, LENZ is eligible to receive up to $85 million in regulatory sales milestones, along with tiered royalties ranging from mid-single digits to low double-digit percentages on net sales in Greater China.?The NDA for VIZZ?in China is due for decision in the first quarter of 2027.
LENZ closed Thursday's trade at $6.50, down 1.22%. 1952.HK closed Thursday's trade at HK$27.4.
GNI Group Ltd. (2160.T) has entered into an agreement to acquire Ayumi Pharmaceutical Holdings Co., Ltd. for approximately 44.8 billion Japanese Yen. The transaction includes Ayumi Pharma's flagship product, Calonal, also known as acetaminophen, which holds more than 80% of Japan's acetaminophen market.
2160.T closed Thursday's trade at 2,685 Japanese Yen.
Clinical Trials - Breakthroughs & Setbacks
Johnson & Johnson (JNJ) reported that its investigational immunoselective treatment?IMAAVY (nipocalimab-aahu) delivered a rapid and durable improvement in haemoglobin levels in patients with warm autoimmune hemolytic anaemia (wAIHA) from its Phase 2/3 ENERGY study. wAIHA has no FDA-approved treatments.
In the study, IMAAVY demonstrated a safety profile consistent with its safety profile in the approved indication of generalised myasthenia gravis, the company stated.
JNJ closed Thursday's trade at $238.33, down 0.07%
Humacyte, Inc. (HUMA), announced positive top-line interim results from the Phase 3 study, dubbed V012, evaluating the Acellular Tissue-Engineered Vessel (ATEV) in female patients undergoing dialysis access.
The trial met its primary endpoint, which is total days free from indwelling catheter until 365 days after access placement, or until access abandonment, whichever occurs first.
Notably, patients implanted with the ATEV had an average of 220 catheter-free days, compared with 129 for patients who received an AV fistula. In primary safety-related factors, patients receiving the ATEV experienced infections at a rate of 6?per 100 patient-years, compared with 23 per 100 patient-years in patients receiving the AV fistula procedure.
HUMA closed Thursday's trade at $1.08, down 19.40.
Eli Lilly and Company (LLY) announced additional positive results from pivotal Phase 3 trials dubbed the TRIUMPH-1 trial for adults with obesity and TRANSCEND-T2D-1 in adults with type 2 diabetes evaluating Retatrutide, an investigational GIP,?GLP-1, and glucagon triple-hormone receptor agonist.
In the trials, Retatrutide showed substantial weight loss along with meaningful improvements in knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and A1C reductions, as well as weight loss?in type 2 diabetes. The types of adverse events seen in the trials were generally consistent with those seen in trials of other incretin-based therapies, noted the firm.
LLY closed Thursday's trade at 1160.95, up 2.16%
Sanofi (SNY) discontinued its Phase 3 MOBILIZE trial of Riliprubart for the treatment of chronic inflammatory demyelinating polyneuropathy, or CIDP, based on findings from an independent data monitoring committee that Riliprubart was unlikely to yield sufficient efficacy in treating CIDP.
Meanwhile, the ongoing Phase 3 VITALIZE trial for Riliprubart in IVIg-treated CIDP patients will continue as planned.
SNY closed Thursday's trade at $44.11, up 1.24
Zealand Pharma A/S (ZEAL.CO)'s partner Boehringer Ingelheim?reported positive trial readouts from?two global Phase III trials named SYNCHRONIZE-1 for adults living with obesity or overweight, without type 2 diabetes and the SYNCHRONIZE-MASLD study for adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD), which evaluated its investigational glucagon/GLP-1 receptor dual agonist?Survodutide.
In SYNCHRONIZE-1, Survodutide showed an average sustained weight loss of up to 16.6% compared with 3.2% in the placebo arm, along with a 34.0% relative reduction in fat loss.
In the SYNCHRONIZE-MASLD trial, Survodutide met its other co-primary endpoint with a relative reduction in body weight of up to 12.2% compared to 1.0% in the placebo arm, and 6 out of 10 patients (61.0%) achieved liver fat normalisation compared to 5.7% in the placebo arm.
Meanwhile, treatment discontinuation rates due to GI adverse events were 19% in the Survodutide arm compared with 2.9% in the placebo arm.
ZEAL.CO closed Thursday's trade at 294.30 Danish Kroner.
Eli Lilly and Company (LLY)?unveiled new?findings based on post-hoc analyses of more than 1,500 female participants in the ATTAIN-1 and ATTAIN-2 clinical trials that evaluated Foundayo, an oral GLP-1 therapy.
In the ATTAIN-1 study, women in perimenopause lost up to 30.4 lbs (14.4%), while those in postmenopause lost up to 28.2 lbs (14.1%). In ATTAIN-2, women taking Foundayo experienced significant weight loss across all stages of menopause, even when living with type 2 diabetes.
LLY closed Thursday's trade at 1160.95, up 2.16%
For More Such Biotech Stock News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Weekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data

Key Points
The company is expanding both approved and pipeline therapies.
New indications could expand the market for existing drugs.
Long-term cash flow growth could support future dividend increases.
That's significantly higher than many other blue-chip healthcare stocks, including Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), and Amgen (NASDAQ: AMGN), all of which yield dividends of roughly 2% or less.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
But dividends don't increase just because management wants them to. They rise because the business generates enough cash to support them.
Following the money
This week, AbbVie presented new data from its blood cancer portfolio at the European Hematology Association (EHA) Congress.
This is one of the world's largest medical conferences focused on blood cancers and disorders, bringing together thousands of physicians, researchers, pharmaceutical companies, and healthcare professionals to present new clinical trial data and discuss emerging treatments.
The reason EHA is important is that companies often use the conference to release new data on cancer drugs, particularly therapies targeting blood cancers. Positive results presented at EHA can support regulatory approvals, label expansions, partnerships, and future revenue growth. That's why AbbVie showcased its new clinical results there.
The company's most recent presentations included data on approved therapies as well as several pipeline candidates. In total, AbbVie showcased 21 presentations spanning multiple blood cancers, including chronic lymphocytic leukemia, follicular lymphoma, multiple myeloma, acute myeloid leukemia, and diffuse large B-cell lymphoma.
AbbVie generated about $61 billion in revenue during 2025, and while immunology drugs receive most of the attention, oncology remains an important contributor.
The company's oncology portfolio generated about $6.7 billion in revenue in 2025. That's not insignificant.
That revenue helps fund research and development, debt reduction, share repurchases, and dividends.
Indeed, oncology helps diversify AbbVie's business.
Diversifying the pipeline
You may remember the company's dependence on Humira.
At its peak, Humira was one of the best-selling drugs in pharmaceutical history, generating about $21 billion in annual revenue.
That concentration created a significant risk because patents eventually expire. And when Humira lost U.S. exclusivity in 2023, and biosimilar generics entered the market, Humira revenue began declining rapidly.
Management saw this challenge coming years in advance and responded by aggressively building new growth platforms across immunology, oncology, and neuroscience.
Today, drugs such as Skyrizi and Rinvoq (used to treat Crohn's disease, ulcerative colitis, and arthritis) are helping offset Humira's decline, while the company's oncology portfolio provides another important source of revenue and cash flow. The result is a much more diversified business than just a few years ago.
Today, AbbVie generates revenue across immunology, neuroscience, and oncology. That has reduced dependence on any single product and created a more resilient cash flow profile.
And that's why the EHA presentations are relevant.
AbbVie is actively expanding the use of existing drugs while advancing newer therapies that could eventually offset declines from older products. The company highlighted encouraging efficacy data across multiple studies, including late-stage programs and investigational treatments targeting difficult-to-treat blood cancers.
Of course, you can't guarantee successful drug development.
Clinical setbacks happen, and not every program succeeds. It's just part of the overall process of developing new therapies.
Still, AbbVie's oncology portfolio is no longer dependent on a single drug. The company now has multiple approved products, several late-stage opportunities, and a broader pipeline than it did just a few years ago.
Now consider that the latest clinical updates will strengthen the revenue engine supporting the dividend over the long term.
AbbVie's oncology business already generates billions of dollars annually, and management continues working to ensure that oncology remains a growth driver rather than a mature business.
That's why the company continues investing heavily in expanding existing therapies into new indications while advancing next-generation treatments for blood cancers and solid tumors.
Every successful clinical trial creates the potential for new approvals, larger patient populations, and longer revenue runways. And because cancer treatments often command premium pricing and can remain on the market for many years, successful oncology drugs can become meaningful cash-generating assets.
And ultimately, it's cash flow that pays dividends.
Should you buy stock in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!*
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 12, 2026.
Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Amgen, and Eli Lilly. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

Key Points
Parabilis and another recent IPO stock each raised more than Moderna -- which had previously been the biggest biotech IPO.
Parabilis’ technology could be a game changer and potentially used across treatment areas.
This year is turning out to be a massive one for initial public offerings, with Cerebras Systems delivering the biggest so far and SpaceX on track to launch the largest ever. On top of that, Anthropic and OpenAI recently filed confidentially with regulators, suggesting they may make market debuts soon.
That activity has been in the technology sector, but another area that's looking hot is the industry of biotech. Kailera Therapeutics got the ball rolling in April, with a biotech IPO that topped the biggest one to date -- that of Moderna, which raised a record $604 million in 2018. And just this week, Parabilis Medicines (NASDAQ: PBLS) topped them all, raising $670 million. And on the stock's first day of trading, it soared 58% to close at a little over $31.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Investors are clearly excited about this biotech company exploring an innovative way to fight cancer and potentially other diseases. Now the question is: After this explosive IPO, is it too late to buy the stock?
Taking on "undruggable" targets
First, let's start out by taking a closer look at Parabilis. The company launched in 2015, built on many years of research out of Greg Verdine's Harvard University lab. He was a co-founder and chief executive officer in the company's earliest days. Verdine's team found a way to target what previously was thought to be "undruggable" -- these are certain proteins that are inside cells and lack the concave surfaces that allow drugs to bind and take action.
Verdine's team created a new drug type, forming peptides into an alpha-helix so that they could enter cells, bind to flat surfaces, and work to fight disease. And so was born the company's Helicon platform.
Today, Mathai Mammen, former global head of research and development at Johnson & Johnson, is CEO of Parabilis -- at the pharma giant, he led his team to the approvals of nine medicines across oncology, immunology, and neuroscience. So Mammen has what it takes to lead Parabilis through the current and next stages of clinical development and into commercialization.
"Promising" results in patients
The biotech's lead candidate, zolucatetide, is set to begin a phase 3 study in desmoid tumors, noncancerous growths that have limited treatment options, in the first half of next year. Parabilis has studied zolucatetide in more than 150 patients so far and delivered "promising" data in a range of tumor types, the company wrote in its prospectus.
Zolucatetide is involved in four phase 1 studies, including hepatocellular carcinoma and colorectal cancer. And the biotech is also developing candidates in preclinical studies and aims to expand this technology into other therapeutic areas beyond oncology in the future.
Parabilis says that Helicons are the only modality out there right now that allows for the entering of cells and the binding to flat surfaces. This ability to make "undruggable" targets "druggable" could be big, particularly if it may be extended across many treatment areas. About 80% of validated disease targets are undruggable today, according to Parabilis.
Parabilis' deepening loss
Now, let's consider the recent IPO and the company's financial picture. Proceeds from the offering will go toward funding zolucatetide's phase 3 study, as well as earlier studies in other indications and earlier-stage research. The company's loss has progressively deepened, to $145 million last year, as R&D costs advanced to $125 million. This isn't surprising for a biotech company at this stage. But these losses and need for ongoing spending to support its programs make Parabilis -- and other biotechs at this moment in their growth stories -- risky investments.
So, considering all of this and the recent double-digit gain on IPO day, is it too late to get in on Parabilis? This biotech offers interesting -- and potentially game-changing -- technology, but it may take several years for this, if successful, to translate into revenue. So, regardless of the stock price, Parabilis isn't the best choice for cautious investors.
If you're an aggressive investor, however, and you're looking for a biotech that potentially may be a big winner down the road -- and you have the patience to buy and hold for several years, Parabilis may be right for you. That said, there's no need to rush in immediately after this spectacular IPO gain. Instead, you're better off waiting for an opportunity to buy on the dip.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 926%* — a market-crushing outperformance compared to 203% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of June 12, 2026.
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Moderna. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?

AbbVie ABBV continues to see strong momentum from Skyrizi and Rinvoq, its two blockbuster immunology medicines. Sales of both drugs not only mitigated the impact of continued erosion in legacy drug Humira but also reaffirmed their role as AbbVie’s key growth drivers.
This growth continued into 2026. In the first quarter, Skyrizi sales increased 29.2% year over year to $4.48 billion, while Rinvoq sales rose 20.2% to $2.12 billion. Together, the products were key contributors to AbbVie's double-digit revenue growth in the quarter. The company subsequently raised its 2026 revenue outlook for both medicines by $100 million each and now expects Skyrizi and Rinvoq to generate $21.6 billion and $10.2 billion in sales, respectively, this year. Combined, Skyrizi and Rinvoq are expected to deliver more than 20% growth in 2026.
A key driver behind this strength is continued demand across inflammatory bowel disease (IBD) indications, including ulcerative colitis (UC) and Crohn's disease (CD). Skyrizi has emerged as a leading therapy in the category, while Rinvoq continues to gain traction following label expansions that support earlier use in treatment. AbbVie also highlighted continued market-share gains and strong new-patient demand for both products in the first quarter.
The growth runway for both medicines remains substantial. AbbVie recently submitted regulatory applications seeking approval of Rinvoq across two indications — vitiligo and alopecia areata — and Skyrizi as a subcutaneous induction option for CD. Additional growth opportunities remain, with Rinvoq being evaluated in late-stage studies for hidradenitis suppurativa and systemic lupus erythematosus, and data readouts expected later this year. Management believes the next wave of Rinvoq indications alone could contribute roughly $2 billion in peak annual sales. Combined with continued market-share gains across psoriasis and IBD, these label expansion opportunities should support sustained growth for both medicines through 2026 and beyond.
ABBV’s Competition in the Immunology Space
Johnson & Johnson JNJ remains one of AbbVie’s strongest competitors in immunology through blockbuster medicines Tremfya and Stelara. While Stelara faces biosimilar competition, J&J continues to strengthen its position with Tremfya, which is approved across multiple immunology indications, including UC and CD. The company also recently gained FDA approval for Icotyde, a new oral immunology therapy that is positioned as a direct competitor to Skyrizi.
Eli Lilly LLY is also expanding its presence in the immunology space. Its IL-23 inhibitor Omvoh is approved for both UC and CD, broadening Eli Lilly’s footprint in the fast-growing IBD market.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 14.81 times forward earnings compared with the industry’s average of 17.67.
Image Source: Zacks Investment Research
Revisions in EPS estimates for 2026 and 2027 have trended higher over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.7% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?

(RTTNews) - Johnson & Johnson (JNJ) has expanded U.S. availability of its TECNIS PureSee intraocular lens (IOL), an extended depth of focus option designed to support visual clarity and quality for patients undergoing cataract surgery.
The company said the broader rollout will help more surgeons and patients access a lens that has already been implanted in more than 500,000 eyes worldwide, with 97% of patients recommending it to others.
Cataracts affect nearly 20% of Americans aged 40 and older, and while cataract surgery is one of the safest and most common procedures— with a success rate near 98%— the choice of lens implanted during surgery plays a major role in determining how well patients see afterward. Many patients also experience presbyopia, the age-related loss of near-vision ability, making lens selection even more important for daily activities such as reading, driving, and using digital devices.
The TECNIS PureSee IOL is built on Johnson & Johnson's TECNIS platform and is designed to support visual clarity and quality across a range of distances. It is the first and only FDA-approved extended-depth-of-focus lens without a warning for loss of contrast sensitivity, an important factor for visual performance in low light or foggy conditions.
The company noted that the lens maintains contrast sensitivity comparable to an aspheric monofocal IOL while providing an extended depth of focus, addressing both cataract-related vision loss and presbyopia in a single procedure.
Johnson & Johnson said the expanded rollout reflects its commitment to innovation in surgical vision and to helping patients make informed decisions about their care. Erin Powers, President, Surgical Vision, North America, Johnson & Johnson stated that patients increasingly want vision solutions that align with their lifestyle needs, and the company aims to support that decision-making process. As part of Cataract Awareness Month, Johnson & Johnson has also introduced a lifestyle-based vision quiz to help patients better understand their visual priorities and discuss appropriate lens options with their eye-care professionals.
Cataract surgeons who participated in clinical evaluations reported that TECNIS PureSee demonstrated similar or even fewer night-vision symptoms compared with monofocal lenses, while offering the added benefit of extended depth of focus. Daniel Chang, MD, Cataract and Refractive Surgeon, Empire Eye & Laser Center, who served as an investigator, described the lens as a "landmark advancement" for the TECNIS platform.
JNJ has traded between $149.04 and $251.71 over the past year. The stock closed Wednesday's trading at $238.49, up 0.63%. In pre-market trading the stock is at $239.59, up 0.45%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

J&J Expands U.S. Availability Of TECNIS PureSee IOL For Cataract Patients

(RTTNews) - Johnson & Johnson (JNJ) on Thursday said it is expanding the U.S. rollout of its TECNIS PureSee intraocular lens, an extended depth of focus lens designed to improve vision for patients undergoing cataract surgery.
The company said TECNIS PureSee is the first and only U.S. Food and Drug Administration-approved extended depth of focus intraocular lens without a warning on loss of contrast sensitivity, a measure of a patient's ability to distinguish objects from their background, particularly in low-light conditions.
Johnson & Johnson said the lens provides strong distance and intermediate vision with some near vision, while 97% of patients reported no very bothersome visual disturbances.
"With the full U.S. availability of TECNIS PureSee IOL, we are expanding access to an important extended depth of focus option that reflects our commitment to innovation, visual quality, and patient satisfaction," said Erin Powers, President, Surgical Vision, North America, Johnson & Johnson.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Johnson & Johnson Expands U.S. Rollout Of TECNIS PureSee Lens

(RTTNews) - Johnson & Johnson (JNJ) reported that its IMAAVY (nipocalimab-aahu) delivered a rapid and durable improvement in hemoglobin levels in patients with warm autoimmune hemolytic anemia (wAIHA), marking a significant step forward for a rare autoimmune disease with no FDA-approved treatments.
The company presented the first comprehensive results from the Phase 2/3 ENERGY study, showing that patients receiving the 30 mg/kg dose achieved a statistically significant and sustained hemoglobin response compared with placebo.
Durable Hemoglobin Gains With Early Onset of Effect
According to the data, patients treated with IMAAVY experienced:
-a mean hemoglobin improvement of at least 1 g/dL as early as Week 1.
-approximately three times as many durable hemoglobin responses vs. placebo by Week 24.
-improvements in fatigue and reductions in corticosteroid use, based on patient-reported outcomes and clinical measures.
The therapy is designed to target pathogenic IgG autoantibodies—the antibodies responsible for destroying red blood cells in wAIHA—while preserving overall immune function.
Bruno Fattizzo, M.D., of the University of Milan noted that the rapid and durable improvements observed in the study could help address the debilitating fatigue commonly experienced by people living with wAIHA.
Understanding the ENERGY Study
The randomized, placebo-controlled ENERGY trial evaluated IMAAVY against a stringent primary endpoint requiring:
- hemoglobin increase of greater than or equal to 2 g/dL
- hemoglobin greater than or equal to 10 g/dL
-maintained for at least three visits over 28 days beginning by Week 16
-without rescue therapy or changes to background medications
Why wAIHA Represents a High Unmet Need
Warm autoimmune hemolytic anemia is a rare, life-threatening condition in which the immune system mistakenly destroys red blood cells. Patients often experience severe fatigue, shortness of breath, and cardiovascular strain.
Despite its seriousness, there are currently no FDA-approved therapies for wAIHA, leaving patients dependent on steroids, immunosuppressants, or transfusions— options that may be ineffective or poorly tolerated.
JNJ has traded between $149.04 and $251.71 over the past year. The stock closed Wednesday's trading at $238.49, up 0.63%. In pre-market trading the stock is at $239.15, up 0.26%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Johnson & Johnson's IMAAVY Shows Rapid And Durable Hemoglobin Improvements In Pivotal WAIHA Study

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Eli Lilly (Symbol: LLY), where a total of 15,976 contracts have traded so far, representing approximately 1.6 million underlying shares. That amounts to about 49.1% of LLY's average daily trading volume over the past month of 3.3 million shares. Particularly high volume was seen for the $1200 strike call option expiring June 12, 2026, with 812 contracts trading so far today, representing approximately 81,200 underlying shares of LLY. Below is a chart showing LLY's trailing twelve month trading history, with the $1200 strike highlighted in orange:
Johnson & Johnson (Symbol: JNJ) saw options trading volume of 37,350 contracts, representing approximately 3.7 million underlying shares or approximately 47.2% of JNJ's average daily trading volume over the past month, of 7.9 million shares. Particularly high volume was seen for the $250 strike call option expiring June 12, 2026, with 13,387 contracts trading so far today, representing approximately 1.3 million underlying shares of JNJ. Below is a chart showing JNJ's trailing twelve month trading history, with the $250 strike highlighted in orange:
And Casey's General Stores, Inc. (Symbol: CASY) saw options trading volume of 2,623 contracts, representing approximately 262,300 underlying shares or approximately 46.5% of CASY's average daily trading volume over the past month, of 563,660 shares. Especially high volume was seen for the $900 strike call option expiring June 18, 2026, with 152 contracts trading so far today, representing approximately 15,200 underlying shares of CASY. Below is a chart showing CASY's trailing twelve month trading history, with the $900 strike highlighted in orange:
For the various different available expirations for LLY options, JNJ options, or CASY options, visit StockOptionsChannel.com.
Further LLY Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.